Cancer stem cells (CSCs) refer to the cells obtained from tumor that posses potential to reproduce all types of cancer cells found in a cancer sample. Cancer stem cells are planned to grow in tumors as a separate population and thereby cause deterioration and metastasis of existing tumor through generation of new tumor. Thus, with advancement in technology especially in cancer stem cells research area, therapies specific to targeting cancer stem cells are expected to improve quality of life and survival cases of cancer patients with metastatic disease
Morbidity and mortality rate of cancer is rising at a faster speed worldwide and thus prevention of cancer and cancer treatment is grabbing attention of cancer researchers globally. Stem cells and cell therapy have shown significant potential to treat cancer effectively. Cancer stem cells (CSCs) have been tested on animal models and have also shown satisfactory results. However, human testing of cancer stem cells is still in its developing stage owing to stringent regulations and ethical issues associated with the same.
Get the Complete Future Market Projections of Cancer Stem Cells at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2733
The ascending rate of mortality due to cancer has prompted researchers and scientists across the globe to tap into the vast pool of medical needs. This has intensified the demand for cancer stem cells. Stem cell research plays a key role in designing a treatment for the cancer patients. The soaring awareness amongst patients about stem cells and cell therapy to treat cancer has also fueled the growth of the global cancer stem cells market. However, the lingering skepticism about cancer stem cells therapy and the stringent regulations surrounding its commercialization have hampered the growth of this market.
The market is expected to overcome this hurdle as the world is staggering under the weight of increasing cancer cases, some of which remain unknown to science. Thus, the widening gap between growing medical needs and lack of treatment options is projected to accelerate the pace of research of stem cell therapy for lung cancer, colorectal cancer, skin cancer, breast cancer, bone cancer, and brain cancer. Changing mindsets of various governments is also projected to boost the market as it will bring in funding for cancer stem cell research.
North America has a dominant position in the global cancer stem cells market. The region is benefitting from the well-equipped research facilities, a significant pool of skilled professionals, and an economy that is sensitive to the development of the health care sector. Europe is expected to follow North America’s lead quite closely in the coming few years. Meanwhile, Asia Pacific is expected to exhibit a remarkable progress in the overall market with governments of China and India taking a noteworthy initiative in advancing their research and development activities to improve medical facilities. Japan is also expected to be a key country in the growth of the cancer stem cells market in the near future.
Some of the key players in the global cancer stem cells market are AdnaGen GmbH, AVIVA Biosciences Corporation, Celula, Inc., Advanced Cell Diagnostics, Inc., Epic Sciences, Inc., Rarecells USA, Inc., Silicon Biosystems, S.p.A., and Fluxion Biosciences, Inc. The research report evaluates the business strategies adopted by these players and recommends strategic changes that players could adopt to earn sizeable revenues in the near future.